HeartCore Sells 51% Sigmaways Stake and $2.19M Debt to Semaphore for Up to $650,000
HeartCore Enterprises agreed on June 22, 2026 to sell its entire 51% stake in Sigmaways, Inc. and $2.19 million in Sigmaways promissory notes to Semaphore Technologies, with the closing on the same day. The up-to-$650,000 price consists of a $1,000 cash payment at closing and an earn-out of up to $649,000 tied to Sigmaways' future gross revenue, and HeartCore also gave up a $350,000 SAFE note as part of a mutual release. The company says the sale removes a loss-making subsidiary with a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026 from its consolidated results.
Key points
- Sold 229,500 shares (51% ownership) of Sigmaways and $2.19 million in promissory notes to Semaphore Technologies; closed June 22, 2026.
- Purchase price up to $650,000: $1,000 cash at closing plus an earn-out of up to $649,000.
- Earn-out equals 10% of Sigmaways gross revenue above $5,500,000 over the 12 months after closing, payable within 10 days after that period.
- Sigmaways had a shareholders' deficit of about $3.6 million (unaudited) as of March 31, 2026; HeartCore contributed a $350,000 SAFE note from Heart-Tech Health, Inc. in a mutual release.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 25, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.